449 related articles for article (PubMed ID: 29117154)
21. Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-κB signaling pathway.
Cheng X; Yao X; Xu S; Pan J; Yu H; Bao J; Guan H; Lu R; Zhang L
Biomed Pharmacother; 2018 Jul; 103():490-498. PubMed ID: 29677534
[TBL] [Abstract][Full Text] [Related]
22. Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.
Rotondi M; Coperchini F; Awwad O; Pignatti P; Di Buduo CA; Abbonante V; Magri F; Balduini A; Chiovato L
Mediators Inflamm; 2016; 2016():8512417. PubMed ID: 27555670
[TBL] [Abstract][Full Text] [Related]
23. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
24. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
25. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
[TBL] [Abstract][Full Text] [Related]
26. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.
Palona I; Namba H; Mitsutake N; Starenki D; Podtcheko A; Sedliarou I; Ohtsuru A; Saenko V; Nagayama Y; Umezawa K; Yamashita S
Endocrinology; 2006 Dec; 147(12):5699-707. PubMed ID: 16959844
[TBL] [Abstract][Full Text] [Related]
27. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
28. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells.
Knauf JA; Ouyang B; Croyle M; Kimura E; Fagin JA
Oncogene; 2003 Oct; 22(44):6830-8. PubMed ID: 14534528
[TBL] [Abstract][Full Text] [Related]
29. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.
Dinets A; Hulchiy M; Sofiadis A; Ghaderi M; Höög A; Larsson C; Zedenius J
Eur J Endocrinol; 2012 Jun; 166(6):1049-60. PubMed ID: 22457234
[TBL] [Abstract][Full Text] [Related]
30. Radiation induced thyroid cancer: fundamental and applied aspects.
Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
[TBL] [Abstract][Full Text] [Related]
31. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
32. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
33. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
35. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
36. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
38. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
39. [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
Zhu XL; Zhou XY; Zhang TM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):87-91. PubMed ID: 16630482
[TBL] [Abstract][Full Text] [Related]
40. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.
Ali HM; Urbinati G; Chapuis H; Desmaele D; Bertrand JR; Couvreur P; Massaad-Massade L
PLoS One; 2014; 9(4):e95964. PubMed ID: 24759995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]